CYP24A1 and cancer: Indeed, this observation is of relevance since clinically, the coadministration of calcitriol and CYP24A1-inactivating compounds can result in a significant increase in calcitriol plasma concentrations [32], with consequential therapeutic benefit in cancer patients, as has been previously described with ketoconazole [33].